Parkinson Disease

FDA clears gene therapy trial for Parkinson disease

Published in Drug Week, September 10th, 2004

Avigen, Inc., (AVGN) announced that the U.S. Food and Drug Administration (FDA) has authorized initiation of the phase I-II clinical trial of AV201 for the treatment of Parkinson disease.

"Mid-to late-stage Parkinson's disease is by and large an untreated condition. AV201 has shown considerable promise as a treatment in animal models of Parkinson's disease, and we are excited to be moving this product into the clinic," said Dawn McGuire, MD, Avigen's chief medical officer.

Parkinson disease (PD) is the second most common neurodegenerative disease, affecting an estimated two million individuals in the United States and Europe.

It...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-09-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry